- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01135290
Post Treatment Care After Chemical Peel or Laser Resurfacing
Evaluation of HP828-101 for Post Treatment Care Following a Chemical Peel or Laser Resurfacing
Study Overview
Study Type
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The informed consent document and photography release must be read, signed, and dated by the subject or the subject's legally authorized representative before conducting any study procedures or exams. In addition, the informed consent and photography release document must be signed and dated by the individual who consents the subject before conducting Visit 1. A photocopy of the signed informed consent document must be provided to the subject, and the original signed document placed in the subject's chart.
- Subjects 18 years of age or older, scheduled to undergo either a medium chemical peel with 35% TCA or a laser resurfacing. Subjects may be of either sex and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
Women of child-bearing potential (those who are not premenarchal, not surgically sterilized [hysterectomy or bilateral oophorectomy], or not post-menopausal) may participate in the study if they meet all of the following conditions:
- they are not breast feeding
- undertake a pregnancy test, which must be negative
- they do not intend to become pregnant during the study
- they are using adequate birth control methods and they agree to continue using those methods for the duration of the study
Adequate birth control methods are defined as: hormonal-topical, oral, implantable, or injectable contraceptives; mechanical-spermicide in conjunction with a barrier such as a condom or diaphragm; IUD; or, surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use an adequate birth control method as described above for the remainder of the study.
NOTE: Women who have had a bilateral tubal ligation are not considered to have been surgically sterilized and must agree to the conditions as specified above.
- Willing and able to make all required study visits.
- Able to follow instructions.
- Undergo a medium grade chemical peel or fractional resurfacing.
Exclusion Criteria:
- Contraindications or hypersensitivity to the use of the study medications or their components (e.g., balsam of Peru, castor oil, or phenoxyethanol).
- Therapy with another investigational agent within thirty (30) days of Visit 1, or during the study.
- Have taken anticoagulants (blood thinners, including aspirin) within two weeks.
- Current smoker.
- Use of oral isotretinoin during the past 12 months, systemic steroids, topical retinoids, or topical corticosteroids within the month prior to the study.
- Have any congenital skin disorder which affects keratinocytes, elastin, or collagen.
- Have any dermatologic disease which may be aggravated or provoked by the wounding procedure.
- Are at risk of keloid or hypertrophic scar formation based on personal or family history, or skin exam.
- Have any skin disorder which causes delayed healing.
- Have any systemic condition that would compromise skin healing.
- The Medical Monitor may declare any subject ineligible for a valid medical reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: A
|
|
OTHER: B
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Physician and subject evaluation ratings of the signs and symptoms of facial skin during post-operative care.
Time Frame: 84 Days
|
84 Days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jeffery Kenkel, MD, University of Texas Southwestern Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 828-101-09-016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemical Peel
-
Ottawa Hospital Research InstituteCompletedSubscapularis Peel | Morselized OsteotomyCanada
-
Baxalta now part of ShireDynPort Vaccine Company LLC, A GDIT CompanyCompletedHealthy Volunteers | Chemical Terrorism | Chemical WarfareUnited States
-
Sun Yat-sen UniversityCompleted
-
DSM Nutritional Products, Inc.TerminatedCellulite (Orange Peel Skin)Brazil
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
SRI InternationalRecruitingToxicity;ChemicalUnited States
-
Assaf-Harofeh Medical CenterUnknown
-
Assistance Publique - Hôpitaux de ParisMission Interministérielle de Lutte contre les Drogues et les Conduites Addictives...Not yet recruitingCHEMICAL SUBMISSION
-
TC Erciyes UniversityEnrolling by invitationPomegranate (P. Granatum) Peel CompressTurkey
Clinical Trials on Aquaphor
-
Stratpharma AGRecruitingRadiation DermatitisUnited States
-
State University of New York - Downstate Medical...Active, not recruiting
-
Stratpharma AGCompletedRadiation DermatitisUnited States
-
M.D. Anderson Cancer CenterCompletedRadiation DermatitisUnited States
-
Johns Hopkins Bloomberg School of Public HealthCompleted
-
ProTechSure Scientific, Inc.Poudre Valley Health SystemTerminated
-
GTO Pharmaceutical, LLCTerminatedFemale Sexual Dysfunction | Vulvovaginal Atrophy | Vulvodynia | Dyspareunia | Vestibulodynia | Postmenopausal Symptoms | Arousal Disorders, Sexual | Genito-Pelvic Pain/Penetration Disorder | Female Sexual Arousal Disorder | Sexual Pain DisordersUnited States
-
Oregon Health and Science UniversityUnknown
-
The University of Texas Health Science Center at...RecruitingCancer of the Head and NeckUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast CarcinomaUnited States